• Urbano Anido Herranz, Ovidio Fernández Calvo, Francisco Javier Afonso Afonso, Sofía Rodríguez Martínez de Llano, Martín Lázaro Quintela, Luis León Mateos, Sergio Vázquez Estévez, and Luis Miguel Antón Aparicio.
• Medical Oncology Department, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela 15706, Spain.
• Expert Rev Anticancer Ther. 2015 Mar 1; 15 (3): 339-48.

AbstractRadionuclides have been widely used for cancer treatment. Recently, new research about radium-223 dichloride has been conducted in prostate cancer, which reveals that it is the first radiopharmaceutical to demonstrate an improvement in overall survival and time to first symptomatic skeletal event in patients with castration resistant prostate cancer with symptomatic bone metastases. This fact has created a new paradigm in the treatment of prostate cancer landscape, where only chemotherapy and hormone therapy had a role, while β-emitters had been confined exclusively to the role of pain relief with no impact on survival. The aim of this review is to outline current treatment approaches for advanced prostate cancer with a focus on the role of radium-223 dichloride, reviewing patients' profile that make them suitable to therapy and chances for further studies.

21 keywords...

hide…